Is PBYI or PDSB more undervalued in 2026?

CirclFi compares Puma Biotechnology Inc (PBYI) and PDS Biotechnology Corporation (PDSB) using 13 institutional-grade valuation models. PBYI has a Quality of Company score of 8.4/10 while PDSB scores 4.0/10.

Which is a better buy — PBYI or PDSB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PBYI and PDSB valuations compare?

PBYI at $7.24 and PDSB at $1.07 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PBYI vs PDSB Valuation Comparison 2026 — Intrinsic Value Analysis

PBYI

Biotechnology

Puma Biotechnology Inc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$7.24

Last close

Models

12/13

Active

PDSB

Biotechnology

PDS Biotechnology Corporation

Quality

4.0

out of 10

Value Trap

LOW

Price

$1.07

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	PBYI Fair Value	PBYI Upside	PDSB Fair Value	PDSB Upside
Bayesian DCF	Intrinsic	$6.50	-10.2%	$0.50	-53.6%
Earnings Power Value	Intrinsic	$4.28	-40.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.34	-40.1%	$0.63	-40.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PBYI vs PDSB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PBYI vs PDSB — Which Stock Is More Undervalued?

PBYI scores higher with a 8.4/10 quality rating vs PDSB's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Puma Biotechnology Inc (PBYI) and PDS Biotechnology Corporation (PDSB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PBYI currently trades at $7.24 with a QOC of 8.4/10, while PDSB trades at $1.07 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).